184 related articles for article (PubMed ID: 30109777)
21. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Jin J; Liu BZ; Wu ZM
J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
[TBL] [Abstract][Full Text] [Related]
23. Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
Chen X; Zhu Q; Liu Y; Liu P; Yin Y; Guo R; Lu K; Gu Y; Liu L; Wang J; Wang Z; Røe OD; Shu Y; Zhu L
PLoS One; 2014; 9(5):e95897. PubMed ID: 24836053
[TBL] [Abstract][Full Text] [Related]
24. [The therapeutic value and safety of icotinib as first-line therapy for advanced non-small cell lung cancer patients].
Chen H; Wang HP; Zhang L; Si XY
Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):39-43. PubMed ID: 28056322
[No Abstract] [Full Text] [Related]
25. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
Liu Y; Zhang Y; Zhang L; Liu B; Wang Y; Zhou X; Li Y; Zhao Q; Gong Y; Zhou L; Zhu J; Ding Z; Wang J; Peng F; Huang M; Li L; Ren L; Lu Y
Oncotarget; 2017 Jul; 8(30):49680-49688. PubMed ID: 28591695
[TBL] [Abstract][Full Text] [Related]
26. Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Lei L; Wang WX; Zhu YC; Li JL; Fang Y; Wang H; Zhuang W; Zhang YB; Wang LP; Fang MY; Xu CW; Wang XJ; Lv TF; Song Y
Cancer Sci; 2020 Feb; 111(2):679-686. PubMed ID: 31828849
[TBL] [Abstract][Full Text] [Related]
27. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R
Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950
[TBL] [Abstract][Full Text] [Related]
28. [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Duan JC; An TT; Wu MN; Yang L; Bai H; Wang ZJ; Wang YY; Zhuo ML; Zhao J; Wang SH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):323-8. PubMed ID: 22883988
[TBL] [Abstract][Full Text] [Related]
29. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
Liu K; Jiang G; Zhang A; Li Z; Jia J
BMC Cancer; 2020 Jan; 20(1):76. PubMed ID: 32000711
[TBL] [Abstract][Full Text] [Related]
30. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Li X; Yang XJ; Sun YF; Qin N; Lü JL; Wu YH; Zhang H; Zhang Q; Zhang SC
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):627-31. PubMed ID: 23159001
[TBL] [Abstract][Full Text] [Related]
31. New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.
Zheng Y; Fang W; Liu X; Xu N
Tumori; 2012; 98(4):e102-4. PubMed ID: 23052173
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Shao L; Zhang B; He C; Lin B; Song Z; Lou G; Yu X; Zhang Y
Chin Med J (Engl); 2014; 127(2):266-71. PubMed ID: 24438614
[TBL] [Abstract][Full Text] [Related]
33. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P
Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563
[TBL] [Abstract][Full Text] [Related]
35. Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type.
Fan T; Zhou JY
J Coll Physicians Surg Pak; 2018 Jun; 28(6):S120-S122. PubMed ID: 29866243
[TBL] [Abstract][Full Text] [Related]
36. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
[TBL] [Abstract][Full Text] [Related]
37. [Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
Nong J; Qin N; Wang J; Yang X; Zhang H; Wu Y; Lv J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 May; 16(5):240-5. PubMed ID: 23676980
[TBL] [Abstract][Full Text] [Related]
38. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z
Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Si JF; Xiang J; Wei JW; Hao Y; Song ZB
Neoplasma; 2022 Jul; 69(4):976-982. PubMed ID: 35603955
[TBL] [Abstract][Full Text] [Related]
40. Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Paik PK; Varghese AM; Sima CS; Moreira AL; Ladanyi M; Kris MG; Rekhtman N
Mol Cancer Ther; 2012 Nov; 11(11):2535-40. PubMed ID: 22896669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]